TrialAmerican journal of respiratory and critical care medicine2023

Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.

Kelly E Dooley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.